About - BMY :

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Employees - 34100, CEO - Dr. Christopher S. Boerner Ph.D., Sector - Healthcare, Country - US, Market Cap - 118.40B

Altman ZScore(max is 10): 1.54, Piotroski Score(max is 10): 5, Working Capital: $5437000000, Total Assets: $93670000000, Retained Earnings: $16097000000, EBIT: -5113000000, Total Liabilities: $76470000000, Revenue: $47435000000

- Current Price $57.33 - Analyst Target Price $60.26

Stats & Key Metrics
TickerBMY
IndexS&P 500
Curent Price 57.33
Change1.83%
Market Cap118.40B
Average Volume11.75M
Income-7258.00M
Sales47.44B
Book Value/Share8.45
Cash/Share3.92
Dividend Est2.39 (4.17%)
Dividend TTM2.40 (4.19%)
Dividend Ex-DateJan 03, 2025
Employees34100
Moving Avg 20days-1.12%
Moving Avg 50days2.14%
Moving Avg 200days16.47%
Shares Outstanding2.03B
Earnings DateOct 31 BMO
Inst. Ownership77.73%
Key Ratios & Margins
Price/Earnings-
Forwad P/E8.10
PE Growth-
Price/Sales2.50
Price/Book6.78
Price/Cash14.62
Price/FCF8.58
Quick Ratio1.09
Current Ratio1.24
Debt/Equity3.00
Return on Assets-7.85%
Return on Equity-31.46%
Return on Investment-10.78%
Gross Margin55.87%
Ops Margin17.62%
Profit Margin-15.30%
RSI51.02
BETA(β)0.45
From 52week Low45.69%
From 52week High-6.14%
Earnings & Valuation
EPS-3.60
EPS next Year7.08
EPS next Qtr1.47
EPS this Year-87.94%
EPS next 5 Year-5.00%
EPS past 5 Year5.14%
Sales past 5 Year16.92%
EPS Y/Y-190.62%
Sales Y/Y5.56%
EPS Q/Q-36.16%
Sales Q/Q8.44%
Sales Surprise5.57%
EPS Surprise20.47%
ATR(14)1.37
Perf Week2.78%
Perf Month-0.95%
Perf Quarter14.64%
Perf Year12.50%
Perf YTD11.73%
Target Price60.26

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer